# Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon Plasma Coagulation Technique

> **NCT03621319** · NA · TERMINATED · sponsor: **Erbe Elektromedizin GmbH** · enrollment: 41 (actual)

## Conditions studied

- Barrett's Esophagus
- High-grade Dysplasia in Barrett Esophagus
- Low Grade Dysplasia in Barrett Esophagus

## Interventions

- **DEVICE:** Hybrid argon plasma ablation (HAPC)
- **DEVICE:** Radiofrequency ablation (RFA)

## Key facts

- **NCT ID:** NCT03621319
- **Lead sponsor:** Erbe Elektromedizin GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-24
- **Primary completion:** 2021-05-05
- **Final completion:** 2021-05-05
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Closure due to the COVID-19 pandemic: Protocol specified procedures could not be followed resulting in unavoidable protocol deviations. Lower enrollment than expected. Competing COVID-19 studies at study sites. No ethical, scientific, safety issues.
- **Last updated:** 2021-07-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03621319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03621319, "Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon Plasma Coagulation Technique". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03621319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*